PIM
MRTX

Partner Investment Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Partner Investment Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,370
Closed -$418K – 72
2019
Q3 		$418K Buy
+5,370
New +$504K 0.72% 45
2019
Q2 		– Sell
-1,309
Closed -$96K – 101
2019
Q1 		$96K Buy
+1,309
New +$89K 0.11% 82

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Partner Investment Management's MRTX Position: Q4 2019 in Review

Partner Investment Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2019, closing a stake of 5,370 shares — an estimated $418K sold.

Partner Investment Management first reported a position in MRTX in Q1 2019 and held it in 2 quarters. The position peaked at $418K in Q3 2019. 190 funds tracked by Wall St. Rank hold MRTX as of Q4 2019.

  • Partner Investment Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Partner Investment Management sold 5,370 Mirati Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $418K.
  • Partner Investment Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 2 quarters.
  • Partner Investment Management's Mirati Therapeutics, Inc. Common Stock position peaked at $418K in Q3 2019.
  • 190 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Partner Investment Management's 13F filing for Q4 2019, filed 14 Feb 2020.